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Summary The prodrug N[4-(daunorubidn-N-carbony-oxymethyl)phenyl] 04i-glucuronyl carbamate (DNR-GA3) was synthesized for specific
acfivation by human fi-glucuronidase, released in necrotic areas of tumour lesions. In vitro, DNR-GA3 was 18 times less toxic than
daunorubicin (DNR) and the prodrug was completely activated to the parent drug by human 0-glucuronidase. The maximum tolerated dose of
DNR-GA3 in nude mice bearing s.c. human ovarian cancerxenografts was 6-10 times higherthan that of DNR. The prodrug was cleared more
rapidly from the circulation (elimination t,2 = 20 min) than the parent drug (elimination t12= 720 min). The anti-tumour effects of DNR-GA3 and
DNR were investigated in four different human ovarian cancer xenografts OVCAR-3, FMa, A2780 and MRI-H-207 at a mean tumour size
between 100 and 200 mm3. In three out offour of these tumour lines, the prodrug given i.v. at the maximum tolerated dose ranging from 150 to
250 mg kg-' resulted in a maximum tumour growth inhibition from 82% to 95%. The standard treatrnent with DNR at a dose of 8 mg kg-' given
i.v. weekly x 2 resulted only in a maximum tumour growth inhibition from 400/o to 47%. Tumour line FMa did not respond to DNR, nor to DNR-
GA3. Treatment with DNR-GA3 was also given to mice with larger tumours that would contain more necrosis (mean size 300-950 mm3). The
specific growth delay by DNR-GA3 was extended from 2.1 to 4.4 in OVCAR-3 xenografts and from 4.4 to 6.0 in MRI-H-207 xenografts. Our
data indicate that DNR-GA3 is more effective than DNR and may be especially of use fortreatnent of tumours with areas of necrosis.
Keywords: anthracycline-glucuronide prodrug; daunorubicin; human lgIucuronidase; human ovarian cancer xenografts; targeting; tumour
therapy
Anthracyclines are known for their broad spectrum of activity in
human malignancies. including breast cancer. lung cancer. ovarian
cancer. sarcoma and lymphoma. Complete remissions are gener-
ally difficult to obtain with standard doses in advanced disease.
The major dose-limiting side-effect of the two principal anthracy-
clines doxorubicin (DOX) and daunorubicin (DNR) is myelo-
suppression. In addition, cardiac toxicity may occur as a result of
chronic exposure to the drug. Attempts are being made to increase
the response rates by giving higher doses of anthracyclines in
combination with colony-stimulating growth factors to reduce
bone marrow toxicity. As an altemative. an increased therapeutic
index could possibly be achieved by prodrugs of anthracyclines.
that are mainly activated at the tumour site (Kearney. 1996:
Sinhababu et al. 1996).
In the past. anthracycline prodrugs have been synthesized for
activation by enzymes that are mainly confined to tumours.
Plasmin is such an enzyme because ofwhich the prodrug peptidyl-
doxorubicin has been developed (Chakravarty et al. 1983). The
prodrug appeared to be a poor plasmin substrate which might be
due to the absence ofa spacer between the drug and the enzymati-
cally cleavable group. Another prodrug synthesized was N-L-
leucyl-DOX to be activated by tumour peptidases (Deprez-de
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Campeneere et al. 1982). In human ovarian cancer xenografts. N-
L-leucyl-DOX was shown to be more effective than DOX (Boven
et al. 1992). Clinical studies on N-L-leucyl-DOX have yet to be
completed.
Human >-glucuronidase is another enzyme in which levels are
elevated in tumour tissue when compared with normal tissues
(Connors and Whisson, 1966). Albin et al (1993) have shown that
the concentration of S-glucuronidase was six times higher in breast
cancer tissue ofpatients than in peritumoral tissue. when measuring
the enzyme activity oftissue homogenates. Bosslet et al (1995) and
Schumacher et al (1996) have shown by enzyme histochemistry
that S-glucuronidase was expressed in a wide range of tumour
types and was particularly localized in necrotic areas. The enzyme
can only be detected in very low concentrations in the circulation
(Fishman. 1970). It is hypothesized that anthracycline-glucuronide
prodrugs may be selectively activated in tumour tissue on the basis
of high fr.glucuronidase levels released by necrotic cells. We have
developed such a glucuronide prodrug of DNR: N-[4-(daunoru-
bicin-N-carbonyl-oxymethyl) phenyll O->-glucuronyl carbamate
(DNR-GA3) (R. G. G. Leenders. submitted: Figure 1).
In the present studies. we compared the antiproliferative effects
of DNR-GA3 and DNR in vitro and their respective elimination
half-life times (t,,:) from the circulation of mice. After determina-
tion of the maximum tolerated dose (MTD) of DNR-GA3 in
tumour-bearing mice. the efficacy of the prodrug was compared
with that of DNR in four human ovarian cancer xenografts. Large
tumours have more necrosis than small tumours and were
expected to contain more extracellular S-glucuronidase.
Therefore. special attention was paid to the influence of the
tumour size on drug effects.
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MATERIALS AND METHODS
Cell lines and reagents
The human oxarian cancer cell line N-IH:OV-CAR-3 (Hamilton et
al. 1983) was orowxn as a monolayer in Dulbecco's modified
Eagle's medium (Life Technologies. Paisley. UK) supplemented
xith 10'; heat-inactix-ated fetal calf serum. 50 IU ml-' penicillin
(ICN. Costa Mesa. CA. USA). and 50 !g ml-' streptomycin (ICN
in a humidified atmosphere containing 5%'; carbon dioxide at 37 C.
Daunorubicin (DNR. Societe Parisienne d'expansion chimique.
Paris. France w xxas purchased as a poxxder. The prodrug \-
[4- daunorubicin-.V'-carbony-1-oxy-methyl)phenN-1] O->-glucuronvl
carbamate (DNR-GA3 has been characterized (Houba et al.
1996a: Leenders et al. 1997). The anthracx-cline moietx of this
prodrug is linked to glucuronic acid Xia a carbamate spacer wxith an
aromatic centre. 4-Aminobenzy-l alcohol (Fluka. Buchs. Germnany-
xxas purchased as a poxxder. Stock solutions of DNR. DNR-GA3
and spacer xxere prepared in sterile water and stored at -20'C.
In vitro antiproliferative effects
The in xitro antiproliferatixe effects of drug. prodrug and spacer
xxere determined wxith the use of OVCAR-3 cells as prexiously
described (Houba et al. 1996a). In short. cells suspended in culture
medium wxere seeded in triplicate in 96-xxell culture plates (20 000
cells per \xell. 10 gl per \xell. Drug. spacer. prodrug or prodrug
xxith excess human 3-glucuronidase xxas added (10 p1 per well) to
gixe final concentrations ranging from I nm to 100 pm. After 24 h.
200 1l of culture medium was added and the cells xxere incubated
for another 72 h. After stainincg with sulphorhodamine B. the
absorbance xxas read at 492 nm. The antiproliferatixe effect xx,as
expressed as the IC, xvalue. xxhich is the (pro(drug concentration
that gixes 50% growxth inhibition xAhen compared wxith control cell
groxxth.
0 HO 0
N N ~~~OH
OMe 0 HO O Daunorubicin
0
HO/NH
0
J Spacer
NH
HO NyaO2C
HO o \-ONO Glucuronide
HO
Figure 1 Chemical structure of prodrug N[4-(daunorubicin-N-carbony)-
oxymethyl) phenyl] O-5glucuronyl carbamate (DNR-GA3). After hydrolysis.
DNR-GA3 is activated to DNR: glucuronic acid and 4-aminobenzyl alcohol
spacer are released
Kinetics of DNR and DNR-GA3 in non-tumour-bearing
mice
BALB/c mice (Harlan Cpb. Zeist. The Netherlands) were injected
i.x. wxith DNR 10 mg kg- or DNR-GA3 10 mg ki-. From aroups
of three mice per time point. serial blood samples w-ere collected
xwith the use of heparinized glass capillaries at 1 min. 10 min.
30 min. 1 h. 4 h. 8 h and 24 h after injection. The samples were
centrifuged at 16 000g for 5 min to separate the plasma. From the
plasma. 1O ul w-as diluted in 140 ul of methanol. incubated at
-20'C for 10 min and centrifuged at 16 000 g for 5 min. From the
supernatant. 100 Lul w-as mixed with '5 il 12 mrs¶ trihydrogen
phosphate and 50 ul was loaded on a high-performance liquid
chromatography (HPLC) C18 reversed-phase column (Chromsep
2 x 100 mm x 4.6 mm. i.d. 3 um: Chrompack. Middelburg. The
Netherlands). The drug or prodrug xas eluted from the column
wxith 15 mx phosphate. 0.5 mx\ triethvlamine and 33% (/X)
acetonitrile at pH 4.0 and detected wxith a fluorescence detector
(Jasco 8'1-FP: Separations. HI Ambacht. The Netherlands) using
an excitation w-axelength of 480 nm and an emission wxaxelength
of 580 nm. Calibration of the system wxas performed as described
bx DeJongetal199fl.
Human ovarian cancer xenografts
Female athvimic nude mice (Hsd: athx\mic nude-nii: Harlan Cpb)
wxere handled under specified pathogen-free conditions. The
human oxvarian cancer xenografts OVCAR-3. FMa. A2780 or
MRI-H-207 haxe been described earlier (Molthoft et al. 1991 f.
The OVCAR-3 tumour line is a poorl differentiated serous
adenocarcinoma with a xolume doubling time of 5.0 daxs. The
FMa tumour line is a poorlv differentiated mucinous adenocarci-
noma with a xolume doublinc time of 5.5 davs. A2780 and MRI-
H-207 tumour lines are undifferentiated carcinomas wxith xolume
doubling times of 2.0 and 3.5 davs respectixely. Tumours from
prexvious recipients were transferred bV implanting tissue fraLt-
ments with a diameter of2-3 mm into both flanks of 8- to 10-wxeek
old mice. Upon growxth. tumours wxere measured by the same
obserx er. The tumour xolume >-as calculated b\- the equation
length x wxidth x thickness x 0.5. and expressed in mm'.
Anti-tumour activity of anthracyclines in vivo
First. the MTD of the prodrug gixen i.x-. >-as determined. At the
MTD. a mean rexersible loss was required of approximately 10c
ofthe initial wxeight x ithin 2 wxeeks after the first injection. Deaths
occurnc wxithin 2 weeks after the final injection wxere considered
as toxic deaths. The MTD of DNR in tumour-bearing mice wxas
considered to be 10 mg kg- i.x. wxeekly x 2. as higher doses
induced ascites (Boxven et al. 1996). The MTD ofDNR-GA3 gixven
once or weekly x 2 xas determined in non-tumour-bearing mice
first and adjusted in tumour-bearing mice.
After defininc the MTD for the prodrug. treatment experiments
xxere carried out. At the start (day 0 mice x ere grouped to obtain
similarities in the mean tumour x-olume. For small tumours. the
mean xolume ranged from 119 to 194 mm and for large tumours
from 337 to 953 mm . Control and treatment groups consisted of
six animals each. DNR xxas gixen in a dose of 8-10 mg kg-; i.X
xxeekly x 2 to mice xxwith small tumours only-. DNR-GAxx was
studied at the MTD i.x. once or wxeekly x 2. Mice wxere xxeighed
tx-ice per xxeek and tumours wxere measured on the same dayvs.
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Figure 2 In vitro antproliferative effects in OVCAR-3 celis exposed to
various concentratons of DNR or DNR-GA3. Cell growth was measured after
72 h by suphorhodamine B staining and was expressed as te percentage of
growth in control cells. (-) DNR; (*) DNR-GA3; (U) DNR-GA3 in the
presence of an excess of human -giucuronKiase. Bars, ± s.d.
Differences in efficacy between treatment groups were
expressed as the percentage of maximum growth inhibition (GI).
The relative tumour volume was expressed by the formula VT/VO
where VT is the volume on any given day and V0 is the volume on
day 0. The ratio between the mean of the relative volumes of
treated tumours and that of control tumours x 100% (T/C%) was
assessed on each day of measurement and used to calculate the GI
(GI = 100% -T/C%). The maximum GI was scaled as follows: GI
.50% was defined as not sensitive. 50% < GI < 75% was defined
as sensitive, and GI >75% was defined as very sensitive (Boven et
al. 1988). The GI range from 40% to 50% was called borderline
sensitive. The efficacy of the treatment was also expressed by
calculating the days for each tumour to double twice in volume
(TD1,4). If a tumour did not reach two volume-doubling times, this
volume was extrapolated from the last two available measure-
ments. Differences in mean TD,I 4 between groups were evaluated
with Student's t-test. In addition. differences in efficacy between
the treatment groups of small vs large tumours were expressed as
the specific growth delay (SGD: Boven et al. 1988). The SGD was
calculated according to the following formula:
SGD = (TDI,, treated - TDI__ control)/TD01 control
RESULTS
In vitro antiproliferative effects
The antiproliferative effects of DNR and DNR-GA3 were deter-
mined by measuring the growth of OVCAR-3 cells with the
Time after administration (h)
Fgure 3 Pharmacoknetics of (U) DNR-GA3 10 mg kg-l or (-) DNR
10 mg kg-', given i.v. to BALB/c mice. At different time points after injection,
plasma was analysed for DNR-GA3 and DNR content by reversed-phase
HPLC as descrbed in Materials and mettods. Bars, ± s.d.
sulphorhodamine B assay. DNR (IC, = 2 gm) was 18 times more
toxic than the prodrug (IC, = 35 )1M) when cells were exposed to
drugs for 24 h. Incubation ofcells with DNR-GA3 in the presence
of excess human $-glucuronidase resulted in an increase of the
antiproliferative effects reaching the same IC,O as for DNR (Figure
2). This indicates that the relatively non-toxic prodrug was
completely activated to the toxic drug by the enzyme.
Decomposition of the carbamate spacer will liberate 4-
aminobenzyl alcohol. When OVCAR-3 cells were incubated with
4-aminobenzyl alcohol alone. no toxicity was observed at concen-
trations up to 100 gm (data not shown).
Kinetics of DNR-GA3 and DNR
The pharmacokinetics of the prodrug and the drug were deter-
mined in BALB/c mice (Figure 3). DNR cleared slowly from the
blood with a terminal tV,: of720 min (n-=3) and was detectable for
more than 24 h in the circulation. DNR-GA3 cleared rapidly with a
terminal t1,2 of 20 min (n=3). At 4 h. the DNR-GA3 concentration
was under the detection limit of0.01 Jm. After the i.v. administra-
tion of DNR-GA3, no DNR was detectable in the plasma of the
mice.
Maximum tolerated dose (MTD) and toxicity
ForDNR. a dose of 10 mg kg-1 i.v. weekly x 2 studied in OVCAR-
3-bearing mice was too toxic because five out of six mice suffered
from ascites and rapid death between 16 and 92 days after the first
injection. DNR 8 mg kg-' i.v. weekly x 2 was well tolerated in
subsequent treatment experiments.
Table 1 MTD determination of DNR-GA3 in OVCAR-3 bearing mice
Treatnert Dose i.v. Days Tunour volune Weight loss Weight day 14 Toxic
(mg kg-') mean s.e.m. % ± sd. % ± sd. deaths
DNR-GA3 100 0 162±36 2.9±0.2 101.1 ±5.9 0/3
DNR-GA3 100 0 659 136 2.4±2.4 109.2 ± 9.5 0/3
DNR-GA3 200 0 246 64 19.0 ± 4.9 84.4± 6.6 0/3
DNR-GA3 250 0 122 26 10.7 ± 5.3 95.9 ± 6.0 1/6
DNR-GA3 250 0 458 107 7.6± 3.1 98.7 ± 2.9 0/6
DNR-GA3 150 0,7 197 50 2.2± 7.1 101.6 ± 5.6 0/6
DNR-GA3 200 0,7 193 49 6.4 ± 8.9 93.6 ± 8.9 0/6
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Figure 4 Tumour growth in mice bearing small or large OVCAR-3. A2780 or MRI-H-207 xenografts after i.v. treatment with maximum tolerated doses of DNR
(day 0. 7) or DNR-GA3 (day 0). A. control (small tumours): 0. DNR 8-10 mg kg-' (small tumours); E. DNR-GA3 150-250 mg kg1 (small tumours): control
(large tumours): =. DNR-GA3 150-250 mg kg- (large tumours). For doses. see also Table 2. Bars. ± s.e.m.
In non-tumour-bearing nude mice. the MTD of DNR-GA3 was
250 mg kg-' i.v. A higher dose ofprodrug was considered to be too
toxic because this resulted in >15% weight loss and several toxic
deaths (data not shown).
In OVCAR-3-bearing mice. we studied DNR-GA3 in a range of
100-250 mg kg-' i.v. Although weight loss at doses of 200-
250 mg kg-' i.v. varied slightly between experiments. a single dose
of 250 mg kg-' was defined as the MTD. This dose resulted in a
maximum weight loss of 10.7% for mice with small and 7.6% for
mice with large OVCAR-3 tumours. In the group with the small
tumours, one out of six mice died within 14 days (Table 1). If
DNR-GA3 was given weekly x 2. doses of 150 mg kg-' and
200 mg kg-' were well tolerated. No toxic deaths occurred and the
weight loss was not more than 6.4%.
While experiments were in progress, it was found that in FMa-.
A2780- and MRI-H-207-bearing mice the weight loss from DNR-
GA3 varied and required adjustment of the dose. The dose of
250 mg kg-' was too toxic for mice bearing small FMa tumours
because the animals developed ascites. and five out of six died
between day 16 and day 36. In mice bearing large FMa tumours. a
dose of 200 mg kg-' caused ascites in two out of six animals.
Smaller doses of DNR-GA3 were not studied in FMa as this dose
of prodrug was ineffective. In A2780-bearing mice, a dose of
200 mg kg-' was too toxic. This resulted in >15% weight loss and
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Figure 5 Tumour growth in mice beanng small OVCAR-3 xe
i.v. treatnent with DNR or DNR-GA3. The arrows show the de
A, control; 0, DNR 8 mg kg-' on days 0, 7; M, DNR-GA3 150
days 0, 7; *, DNR-GA3 200 mg kg-' on days 0, 7. Bars. + s.e
toxic deaths occurred in four out of six mice (sn
tumours). The MTD of DNR-GA3 in A2780-bear
150 mg kg-I resultinr in a maximum weight loss of9
for small-and large-tumour-bearing animals respecti
with larme MRI-H-207 tumours. a dose of 200 mg k
<15%7 weight loss and one out of six toxic deaths:
slirhtly. but not significantlv. less toxic in mice I
MRI-H-207 tumours and was considered as the MTI
Anti-tumour activity of DNR and DNR-GA3 in vivo
The anti-tumour effects of DNR were different among the four
human ovarian cancer xenografts (Table 2. Figure 4). The
OVCAR-3. A'780 and MRI-H-207 tumour lines were borderline
sensitive with maximum GI Xalues of47%7. 419% and 40%5 respec-
tively. whereas the FMa tumour line was not sensitive to DNR.
At equitoxic doses. the molar amount of DNR-GA3 that could
be administered was six- (A2780) to tenfold (OVCAR-3) higher
than that of the parent drug. The FMa tumour line wAas not sensi-
tive to DNR-GA3. In three out of four xenogorafts (OVCAR-3.
A2780 and MRI-H-207) that were sensitive to DNR. DNR-GA3
induced a maximum GI ofapproximately 90%7. which was consid-
erably higher than that of DNR (Table 2. Figure 4). The better anti-
tumour effect of DNR-GA3 was also demonstrated in a further
30 35 increase in two tumour v-olume-doubling times. wAhich was sianifi-
cant for OVCAR-3 and MRI-H-207 xenografts (P <0.02. Table 2).
DNR-GA3 treatment in large tumours appeared to result in a
ays of treatment better inhibition of growth than the same treatment in small
mg kg-' on tumours in two out of three tumour lines with sensitivity to DNR.
.m. The SGD increased in OVCAR-3 tumours from 2.1 to 4.4. and in
MRI-H-207 tumours from 4.4 to 6.0.
nall and large Dose dependency
ing mice was
1.4% and 9.7% To determine whether a higher dose of DNR-GA3 was more
ivelv. In mice effective in the treatment of tumour-bearing mice than a lower
g-' resulted in dose. mice bearing OVCAR-3 xenoggrafts were injected with
this dose was 150 mg kg-' DNR-GA3 weekly x 2 or 200 mg kg-' DNR-GA3
bearinga small weekly x 2. Control groups were treated with DNR weekly x 2. or
D. receixed no treatment. Both prodrug doses were more effectiVe
Table 2 Treatment with DNR or DNR-GA3 in mice bearing human ovanan cancer xenografts
Tumour Treatment Size Dose i.v. Days Tumourvolume Weight loss Weight day 14 Toxic Gl%c T b
line (mg kg-') mean ± s.e.m. % ± s.d. % ± s.d. deaths (day) days ± s.e.m. (n)
OVCAR-3 Control Small 119 ± 29 n.a-a 104.3 ± 3.9 0/6 n.a. 11.0 ± 1.0 (9)
DNR Small 10 0.7 132+±30 2.4 ± 2.2 115.9±9.0 0/6 47(33) 18.8+±2.8(10)'
DNR-GA3 Small 250 0 122±26 10.7+5.3 95.9+6.0 1/6 82(33) 33.9±4.6(8)-"
Control Large 390±97 n.a. 110.5±1.2 0/6 n.a. 20.4±1.7(9)
DNR-GA3 Large 250 0 458_±107 7.6±3.1 98.7_±2.9 0/6 87(34) 109.9±26.0(10)'
Fma Control Small 158_±26 n.a. 103.0_5.6 0/6 n.a. 12.5_0.8(12)
DNR Small 8 0,7 174±29 0.0 105.4±5.8 0/6 0(24) 12.1 _0.8 (12)
DNR-GA3 Small 250 0 162±37 9.6±3.8 93.2 5/6 24(24) 14.5 _1.0(2)
Control Large 359±58 n.a. 103.1 ±5.0 0/6 n.a. 19.5±2.3(6)
DNR-GA3 Large 200 0 404_±61 11.4±10.0 96.4_±8.6 2/6 15(24) 29.0_ 5.2 (8)
A2780 Control Small 192 45 n.a. 102.2 0/6 n.a. 3.2 0.7 (9)
DNR SmaJI 8 0.7 163±54 0.0±4.0 101.6±6.5 0/6 41(11) 5.2_1.0 (11)
DNR-GA3 Small 150 0 171 _25 9.4±9.2 99.1 ±10.8 0/6 86(14) 7.6_1.1 (11)-
Control Large 953 239 n.a. 109.3 0/6 n.a. 5.3 ± 0.9 (9)
DNR-GA3 Large 150 0 705±117 9.7±9.2 108.3±12.0 0/6 90(14) 11.6 _1.0(12)-
MRI-H-207 Control Small 180 ± 32 n.a. 113.6 ± 4.3 0/6 n.a. 7.2 ± 0.3 (12)
DNR Small 8 0.7 182 ± 35 1.8 8 3.8 105.6 ± 6.0 0/6 40 (22) 9.0 0.4 (12)-
DNR-GA3 Small 100 0 191 ±24 0.0± 1.8 107.6_±4.3 0/6 67 (22) 12.9_1.0 (12)"
DNR-GA3 Small 200 0 194± 19 9.7± 9.6 95.2 ± 16.4 0/6 95 (22) 38.9± 6.0 (8)--
Control Large 337± 50 n.a. 114.9 ± 1.8 0/6 n.a. 8.3+ 0.5 (12)
DNR-GA3 Large 100 0 485± 81 0.7+ 8.1 107.6 ± 7.9 0/6 52 (18) 12.5± 1.1 (11)-
DNR-GA3 Large 200 0 343_57 19.4±8.1 82.3±9.0 1/6 96(18) 57.9_10.9(9)'
*P c0.02 when compared with control; P < 0.02 when compared with DNR. an.a., notapplicable:; tumour volume-doubling time in days from a relative volume of
1 to 4: cmaximum growth inhibiion.
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than DNR (P<0.01). Also. the higher dose of 2 x 200mg kg-'
DNR-GA3 was slightly. but not significantly. more effective than the
lower dose of 2 x 150 mg kg-' DNR-GA3 (Figure 5). Similar data
were obtained for the MRI-H-207 tumour line in which 200 mg kg-'
DNR-GA3 on day 0 was more effective than the lower dose of
100 mg kg-' DNR-GA3 on day 0(P < 0.002) (Figure 4 and Table 2).
DISCUSSION
The objective ofthis study was to investigate the potential increase
in the therapeutic index of the glucuronide prodrug DNR-GA3
when compared with DNR. In vitro. the prodrug was 18-fold
less toxic than DNR. In mice bearing human ovarian cancer
xenografts. the MTD ofDNR-GA3 was six- to tenfold higher than
that ofDNR. The prodrug was apparently activated in the tumours
by f-glucuronidase and inhibited tumour growth in human ovarian
cancer xenografts that were sensitive to the parent drug DNR. In
these three xenografts (OVCAR-3. A2780. and MRI-H-207). the
inhibitory effect at MTD was better than the tumour growth delay
obtained with the parent drug.
The different DNR-glucuronide prodrugs synthesized were
designed to be rapidly activated in the presence of human >-
glucuronidase. DNR-GA3 was most rapidly activated in vitro by
human o-glucuronidase (Houba et al. 1996a). and was chosen for
in vivo analysis. DNR-GA3 is stable in vivo. it is a hydrophilic
molecule that hardly passes through the cell membrane into the
cell. DNR-GA3 will. therefore. not be activated by intracellularf-
glucuronidase. Activation in the circulation is also less likely as
the plasma levels of P-glucuronidase are very low (Fishman.
1970). Bosslet et al (1995) and Schumacher et al (1996) have
demonstrated high levels of f-glucuronidase in necrotic areas in
tumours. Therefore. it could be expected that DNR-GA3 will be
activated selectively by human S-glucuronidase released from
necrotic tumour cells.
The difference in MTD between DNR-GA3 and DNR in mice
bearing human ovarian cancer xenografts may be explained by the
more rapid clearance ofDNR-GA3 (elimination t,:, = 20 min) than
that ofDNR (elimination ty. = 720 min) from the circulation. Thus
far. we have no information on the nature ofthe dose-limiting toxi-
city in mice. We observed. however. the formation of ascites at
higher doses of DNR-GA3 as also described for DNR (Boven et
al. 1996). The variation in the MTD of DNR-GA3 found among
the four different human ovarian cancer xenografts may possibly
be clarified by differences in activation and leakage of DNR from
the tumours into the circulation.
The treatment expenrments showed that the prodrug DNR-GA3
induced better inhibition of growth in three out of four human
ovarian cancer xenografts than equitoxic doses ofDNR (OVCAR-
3. A2780 and MRI-H-207). This observation may be explained by
higher local DNR concentrations in the tumour from activated
DNR-GA3. Earlier. it has been demonstrated that there is a steep
dose-response curve for anthracyclines (Frei and Canellos. 1980).
Bosslet et al (1995) have described that s.c. grown LoVo colon
cancer xenografts with a diameter larger than 2 mm had necrotic
areas. where S-glucuronidase was present in high concentrations.
This group has also demonstrated that a glucuronyl-spacer-DOX
prodrug showed better therapeutic effects than DOX.
It was hypothesized that large tumours contain more necrosis
and. thus. more $-glucuronidase would be available to activate
DNR-GA3. Indeed, we calculated a relatively longer increase in
two volume-doubling times for large tumours of the OVCAR-3
and the MRI-H-207 tumour lines when compared with the values
of the respective small tumours. With respect to the clinic. this
finding is of interest because the treatment of patients with large
tumour deposits remains achallenge.
The administration of anthracycline prodrugs to be activated at
the tumour site may induce an even better growth inhibition when
combined with a second approach: antibody-directed enzyme
prodrug therapy (ADEPT: Bagshawe et al. 1988). In ADEPT.
prodrugs are activated in the tumour by an administered tumour-
specific monoclonal antibody-enzyme conjugate. In our point of
view. DNR-GA3 is very suitable for ADEPT. We have shown
earlier that a conjugate of monoclonal antibody 323/A3 and
human f-glucuronidase bound to tumour cells can activate DNR-
GA3 in an efficient manner (Haisma et al. 1992: Houba et al.
1996b). Ifsuch a tumour-specific conjugate is administered before
DNR-GA3 injection. activation could also occur in the non-
necrotic smaller tumour lesions.
In conclusion. our findings suggest that the glucuronidated
anthracycline DNR-GA3 may have a better therapeutic index in
advanced solid tumours in which anthracychnes are considered for
treatment.
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